Gustave Roussy, Cancer Campus, Grand Paris

This study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the ri…

This phase 2 trial tested a combination of two drugs, niraparib and dostarlimab, in 51 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. However, the study was terminated…

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This phase 2 trial tested two stronger treatment plans for children with very high risk neuroblastoma whose cancer did not respond well to initial chemotherapy. The treatments combined radioactive therapy (mIBG), chemotherapy drugs (topotecan and thiotepa), and a stem cell transp…

This pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…

This study tested whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could increase immune cell activity in early-stage breast cancer. It involved 33 patients with triple-negative or HER2-positive breast cancer. The …